Clinical Trial: Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Severe Acute Pancreatitis
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following
Brief Summary: Cytokines such as such as TNF-a, IL-1, IL-6 correlate with the severity of pancreatitis.Neuroendocrine pathways, such as the sympathetic nervous system or parasympathetic nervous system, in turn, have some impact on the immune systems, through a-2 adrenoreceptor stimulation or the cholinergic anti-inflammatory pathway. The investigators aim to use Dexmedetomidine Hydrochloride to decrease the activity of sympathetic nervous system, thus relieve inflammation response.
Detailed Summary:
Infected pancreatic necrosis (IPN) and multiple organ dysfunction syndrome (MODS) are major complications of acute pancreatitis which determine disease severity and outcome.It is concluded that systemic inflammation in SAP characterized by the endocrine release of different cytokines, such as TNF-a, IL-1, IL-6 and many others. These cytokines correlate with the severity of pancreatitis.
Neuroendocrine pathways, such as the sympathetic nervous system or parasympathetic nervous system, in turn, have some impact on the immune systems, through a-2 adrenoreceptor stimulation or the cholinergic anti-inflammatory pathway. Dexmedetomidine Hydrochloride is a high selected a-2 adrenoreceptor agonists.Some studies have shown that Dexmedetomidine Hydrochloride could improve the outcome of sepsis patients and decrease the development of organ failure.
The investigators aim to use Dexmedetomidine Hydrochloride to decrease the activity of sympathetic nervous system,thus relieve inflammation response.
Sponsor: Nanjing University School of Medicine
Current Primary Outcome: Incidence rate of Organ failure [ Time Frame: 30 days after Incidence of the disease ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Infected pancreatic necrosis [ Time Frame: 30 days after Incidence of the disease ]
Original Secondary Outcome: Same as current
Information By: Nanjing University School of Medicine
Dates:
Date Received: February 14, 2016
Date Started: February 2016
Date Completion: August 2017
Last Updated: February 20, 2016
Last Verified: February 2016
